imatinib mesylate has been researched along with Hyperplasia in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (61.54) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, L; Du, J; Fan, X; Kong, X; Li, A; Liang, L; Lin, L; Song, J | 1 |
| Hartney, TJ; Jun, JY; Pichavaram, P; Segar, L; Shawky, NM | 1 |
| Adam, RM; Dietz, HG; Herlemann, A; Kappler, R; Preis, L; Stehr, M | 1 |
| Aizawa, Y; Asami, F; Higashimura, M; Hirono, S; Ikarashi, N; Isoda, M; Kato, K; Kitajima, T; Makiyama, Y; Minagawa, S; Moriyama, M; Oda, M; Otaki, K; Ozawa, T; Saigawa, T; Toba, K | 1 |
| Aavik, E; Hayry, P; Lehti, S; Savolainen-Peltonen, H; Tigerstedt, NM | 1 |
| Hwang, YY; Kwong, YL; So, JC; Tse, E; Wan, TS | 1 |
| Asuzu, DT; Bardsley, MR; Farrugia, G; Hayashi, Y; Horváth, VJ; Lomberk, GA; Lorincz, A; Ordog, T; Popko, LN; Redelman, D; Rubin, BP; Urrutia, RA; Young, DL | 1 |
| Abdulkadir, NA; Cetinkaya, M; Demirturk, K; Gur, S; Hellstrom, WJ; Karabakan, M; Ozgur-Akdemir, A; Volkan-Oztekin, C | 1 |
| Druker, BJ; Frater, JL; Hrisinko, MA; Peterson, LC; Resta, D; Riley, MB; Tallman, MS; Variakojis, D | 1 |
| Hino, N; Myojo, T | 1 |
| Hyodo, H; Ito, T; Katayama, Y; Kimura, A; Miyoshi, N; Niimi, H; Tanaka, H | 1 |
| Aavik, E; Aavik, S; Hayry, P; Lehti, S; Petrov, L; Vamvakopoulos, JE | 1 |
| Hong-eng, S; Limsuwan, A; Pakakasama, S; Rochanawutanon, M | 1 |
1 trial(s) available for imatinib mesylate and Hyperplasia
| Article | Year |
|---|---|
Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
Topics: Antineoplastic Agents; Benzamides; Biopsy; Bone Marrow; Cytogenetic Analysis; Drug Resistance; Fibrosis; Fusion Proteins, bcr-abl; Histiocytes; Humans; Hyperplasia; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Megakaryocytes; Piperazines; Pyrimidines; Reticulin; Reverse Transcriptase Polymerase Chain Reaction | 2003 |
12 other study(ies) available for imatinib mesylate and Hyperplasia
| Article | Year |
|---|---|
Treatment with imatinib was useful to delay the neointimal hyperplasia of aortocaval fistula in adenine-induced renal failure rats.
Topics: Animals; Constriction, Pathologic; Fistula; Hyperplasia; Imatinib Mesylate; Neointima; Proto-Oncogene Proteins c-kit; Rats; Renal Insufficiency | 2023 |
Imatinib improves insulin resistance and inhibits injury-induced neointimal hyperplasia in high fat diet-fed mice.
Topics: Animals; Diet, High-Fat; Femoral Artery; Hyperplasia; Imatinib Mesylate; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Neointima; Protein Kinase Inhibitors | 2021 |
Platelet Derived Growth Factor Has a Role in Pressure Induced Bladder Smooth Muscle Cell Hyperplasia and Acts in a Paracrine Way.
Topics: Blotting, Western; Cell Proliferation; Child; Gene Knockdown Techniques; Humans; Hydrostatic Pressure; Hyperplasia; Imatinib Mesylate; In Vitro Techniques; Lovastatin; Muscle, Smooth; Paracrine Communication; Phosphorylation; Platelet-Derived Growth Factor; Real-Time Polymerase Chain Reaction; Receptor, Platelet-Derived Growth Factor alpha; Urinary Bladder; Urinary Bladder Neck Obstruction; Urodynamics | 2015 |
Imatinib mesilate inhibits neointimal hyperplasia via growth inhibition of vascular smooth muscle cells in a rat model of balloon injury.
Topics: Animals; Benzamides; Catheterization; Cell Division; Cells, Cultured; Disease Models, Animal; Hyperplasia; Imatinib Mesylate; Male; Muscle, Smooth, Vascular; Piperazines; Pyrimidines; Rats; Rats, Sprague-Dawley; Tunica Intima; Tunica Media | 2008 |
Mechanisms behind the synergistic effect of sirolimus and imatinib in preventing restenosis after intimal injury.
Topics: Animals; Aorta; Benzamides; Blood Cell Count; Drug Synergism; Hyperplasia; Imatinib Mesylate; LIM Domain Proteins; Male; Microfilament Proteins; Muscle Proteins; Muscle, Smooth, Vascular; Nuclear Proteins; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Rats; Rats, Wistar; Sirolimus; Tunica Intima; von Willebrand Factor | 2009 |
Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Topics: Benzamides; Biopsy, Needle; Bone Marrow; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Female; Humans; Hyperplasia; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Neutropenia; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2009 |
Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors.
Topics: Animals; Antigens, CD34; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Cell Differentiation; Cell Proliferation; Cell Survival; Cells, Cultured; Clone Cells; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Hyaluronan Receptors; Hyperplasia; Imatinib Mesylate; Interstitial Cells of Cajal; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Nude; Mutation; Neoplastic Stem Cells; Piperazines; Proto-Oncogene Proteins c-kit; Pyrans; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Time Factors; Tumor Burden | 2010 |
Imatinib mesylate (Gleevec) as protein-tyrosine kinase inhibitor elicits smooth muscle relaxation in isolated human prostatic tissue.
Topics: Adrenergic alpha-Antagonists; Aged; Benzamides; Humans; Hyperplasia; Imatinib Mesylate; Male; Middle Aged; Muscle Contraction; Muscle Relaxation; Muscle, Smooth; NG-Nitroarginine Methyl Ester; Piperazines; Prostate; Prostatic Diseases; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines | 2011 |
Complete remission from chronic myelogenous leukemia--blastic crisis caused by reduced intensity stem cell transplantation following partial remission due to imatinib.
Topics: Benzamides; Blast Crisis; Bone Marrow; Genes, abl; Humans; Hyperplasia; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Translocation, Genetic | 2004 |
Use of imatinib mesylate for favorable control of hypercalcemia mediated by parathyroid hormone-related protein in a patient with chronic myelogenous leukemia at blast phase.
Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow Cells; Female; Humans; Hypercalcemia; Hyperplasia; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Parathyroid Hormone-Related Protein; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2005 |
Synergistic suppression of rat neointimal hyperplasia by rapamycin and imatinib mesylate: implications for the prevention of accelerated arteriosclerosis.
Topics: Angioplasty, Balloon; Animals; Aorta, Abdominal; Arteriosclerosis; Benzamides; Drug Synergism; Hyperplasia; Imatinib Mesylate; Male; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Rats; Rats, Wistar; Sirolimus | 2006 |
Pulmonary arterial hypertension after childhood cancer therapy and bone marrow transplantation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; Female; Humans; Hyperplasia; Hypertension, Pulmonary; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Vasodilator Agents | 2006 |